@article{31912e090bc347679108dd50f69e2443,
title = "Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection model",
abstract = "About 20–25% of dengue virus (DENV) infections become symptomatic ranging from self-limiting fever to shock. Immune gene expression changes during progression to severe dengue have been documented in hospitalized patients; however, baseline or kinetic information is difficult to standardize in natural infection. Here we profile the host immunotranscriptome response in humans before, during, and after infection with a partially attenuated rDEN2Δ30 challenge virus (ClinicalTrials.gov NCT02021968). Inflammatory genes including type I interferon and viral restriction pathways are induced during DENV2 viremia and return to baseline after viral clearance, while others including myeloid, migratory, humoral, and growth factor immune regulation factors pathways are found at non-baseline levels post-viremia. Furthermore, pre-infection baseline gene expression is useful to predict rDEN2Δ30-induced immune responses and the development of rash. Our results suggest a distinct immunological profile for mild rDEN2Δ30 infection and offer new potential biomarkers for characterizing primary DENV infection.",
author = "Hanley, {John P.} and Tu, {Huy A.} and Dragon, {Julie A.} and Dickson, {Dorothy M.} and Rio-Guerra, {Roxana del} and Tighe, {Scott W.} and Eckstrom, {Korin M.} and Nicholas Selig and Scarpino, {Samuel V.} and Whitehead, {Stephen S.} and Durbin, {Anna P.} and Pierce, {Kristen K.} and Kirkpatrick, {Beth D.} and Rizzo, {Donna M.} and Seth Frietze and Diehl, {Sean A.}",
note = "Funding Information: We thank Pheobe Laaguiby and Jess Hoffman of the University of Vermont Integrative Genomics Resource (VIGR) for technical expertise in preparation of samples. We thank Roxana del Rio-Guerra for assistance in design and optimization of the flow cytometry panel. We also thank Joe Boyd and Adelaide Rhodes for assistance in analysis. This work was funded by a pilot grant from the UVM Larner College of Medicine and College of Engineering and Mathematical Science (to S.A.D., S.V.S., and D.M.R.), by the National Institute of Health (P20GM125498 to B.D.K., Project 4 to S.A.D. and U01AI141997 to S.A.D. and B.D.K.) and the Bill and Melinda Gates Foundation (OPP1109415). The next-generation sequencing was performed in the VIGR Massively Parallel Sequencing Facility and was supported by the UVM Cancer Center, Lake Champlain Cancer Research Organization, UVM College of Agriculture and Life Sciences, and the Larner College of Medicine, and in part by National Institutes of Health (NIH) grant P30-GM118228. The University of Vermont Bassett Flow Cytometry and Cell Sorting Facility and supported by NIH grants S10-ODO18175 and P30GM118228 with the Cytek Aurora supported by S10-ODO026843. The clinical trial was supported by the National Institute of Allergy and Infectious Diseases (NIAID) Intramural Research Program contract HHSN272200900010C. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
month = may,
day = "24",
doi = "10.1038/s41467-021-22930-6",
language = "English (US)",
volume = "12",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",
}